MIDDLE EAST AND TURKEY CHRONIC LIVER DISEASE (CLD) THERAPEUTICS MARKET ANALYSIS

Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, by Disease Type (Hepatitis, Alcohol Induced Liver Disease, Liver Cancer, Fatty Liver Disease, and Others), by Drug Class (Chemotherapy Drugs, Targeted therapy, Vaccines, Immunoglobulin, and Others), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country (Turkey, Saudi Arabia, Israel, UAE, Egypt, and Rest of Middle East and Turkey) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Feb 2022
Code : CMI4920
Pages :211
Formats :
Excel and PDF
Industry : Pharmaceutical

Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics MarketSize and Trends

Middle East and Turkey chronic liver disease (CLD) therapeutics market size is estimated to be valued at US$ 1,015 million in 2021 and is expected to exhibit a CAGR of 5.8% over the forecast period (2021-2028).

Figure 1. Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Value (US$ Mn), by Region/Country, 2021

Figure 1.1 Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Value (US$ Mn), by Region/Country, 2028

Chemotherapy Drugs segment is expected to hold largest market share in the Middle East and Turkey chronic liver disease (CLD) therapeutics market

Since cancer cells grow and multiply much faster than most of the cells in body, chemotherapy is most often utilized for cancer treatment. The increasing incidence of liver cancer and launch of novel products for cancer treatment are some of the factors, which are expected to drive the Chemotherapy Drugs segment growth. According to the International Agency for Research on Cancer (IARC), age-standardized incidence rate (ASIR) for liver cancer was 4.5 per 100,000 people in 2018 in Saudi Arabia.